Y-box Binding Protein-1 at the Crossroads of DNA Damage Response and Tumor Immune Evasion
Tumor response to radiotherapy is shaped by multiple factors including immune modulation, tumor microenvironment and genetic factors. Among these, the Y-box binding protein-1 (YB-1) is a multifunctional DNA/RNA-binding protein frequently overexpressed in tumors. YB-1 controls the activation of DNA damage response (DDR) signaling following radiotherapy. Emerging evidence suggests that the role of YB-1 extends beyond DDR regulation to shaping tumor-immune interactions by regulating cytokine production, promoting immune evasion, and altering immune checkpoint expression. Elucidating these immune-related functions of YB-1 may uncover novel mechanisms of tumor immune evasion and identify novel therapeutic targets to enhance cancer immunotherapy. This mini-review summarizes current insights into the role of YB-1 in immune regulation, highlighting its impact on tumor immunity and potential clinical applications.
Authors
- Quaovi H. Sodji (ORCID: https://orcid.org/0000-0002-9469-1388)
- Mahmoud Toulany (ORCID: https://orcid.org/0000-0002-8868-6523)
Institutions
- University of Wisconsin–Madison (US)
- University of Wisconsin Carbone Cancer Center (US)
- William S. Middleton Memorial Veterans Hospital (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1093/jncics/pkag044
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.00